OTCMKTS:STDAF STADA Arzneimittel Aktiengesellschaft (STDAF) Stock Price, News & Analysis $110.42 0.00 (0.00%) As of 10/24/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About STADA Arzneimittel Aktiengesellschaft Stock (OTCMKTS:STDAF) Get STDAF alerts:Sign Up Key Stats Today's Range$110.42▼$110.4250-Day Range$110.42▼$110.4252-Week Range$75.15▼$115.00VolumeN/AAverage Volume180 shsMarket Capitalization$6.88 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview STADA Arzneimittel Aktiengesellschaft is a Germany-based pharmaceutical company specializing in the development, manufacturing and marketing of generic medicines and over-the-counter (OTC) healthcare products. Headquartered in Bad Vilbel near Frankfurt, STADA operates a network of production sites, research facilities and sales offices across Europe, Latin America and parts of Asia, serving more than 100 countries worldwide. The company’s product portfolio encompasses a broad range of therapeutic areas, including pain management, cardiovascular care, central nervous system treatments, dermatology and respiratory medicines. In the generics segment, STADA offers off-patent prescription drugs under its own labels and through licensing partnerships. Its consumer healthcare division markets well-known OTC brands, such as analgesics, allergy remedies and self-care solutions for digestive health. STADA also provides contract development and manufacturing services (CDMO) for third-party pharmaceutical and biotech customers, leveraging its formulation expertise and production capacity. This business line complements its core offerings by supporting clients with product development, regulatory filings and scalable manufacturing at global sites. Founded in 1895, STADA transitioned from a regional German firm to an international player over the course of the 20th and early 21st centuries. After listing on the Frankfurt Stock Exchange, the company was taken private in 2017 through a consortium of private-equity investors. Today, it is guided by an experienced management board based at its headquarters, with a focus on expanding its generic and consumer healthcare footprints in established and emerging markets.AI Generated. May Contain Errors. Read More Receive STDAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STDAF Stock News HeadlinesStada Arzneimittel AG Registered Shares (STDAF)April 9, 2026 | nasdaq.comSTAFF NEWSFebruary 22, 2024 | washingtonpost.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)KPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comSTADA Arzneimittel AG V (SAZA)July 21, 2023 | investing.comCBI hired 'toxic' staff and failed to sack offendersMay 30, 2023 | bbc.co.ukSartorius Aktiengesellschaft 2022 Q4 - Results - Earnings Call PresentationJanuary 28, 2023 | seekingalpha.comSee More Headlines STDAF Stock Analysis - Frequently Asked Questions How have STDAF shares performed this year? STADA Arzneimittel Aktiengesellschaft's stock was trading at $110.42 at the beginning of the year. Since then, STDAF stock has increased by 0.0% and is now trading at $110.42. How do I buy shares of STADA Arzneimittel Aktiengesellschaft? Shares of STDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolOTCMKTS:STDAF Previous SymbolNASDAQ:STDAF CIKN/A Webwww.stada.com Phone(496) 101-6030Fax49-61-0160-3259Employees12,500Year Founded1895Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.23 Current Ratio1.54 Quick Ratio0.99 Sales & Book Value Annual Sales$3.84 billion Price / Sales1.79 Cash Flow$11.12 per share Price / Cash Flow9.93 Book Value$23.11 per share Price / Book4.78Miscellaneous Outstanding Shares62,342,000Free FloatN/AMarket Cap$6.88 billion OptionableNot Optionable Beta0.38 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:STDAF) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share STADA Arzneimittel Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.